Macitentan
Catalog No.S8051 Synonyms: ACT 064992
Molecular Weight(MW): 588.27
Macitentan is an orally active, non-peptide, dual ETA/ETB (endothelin) receptor antagonist with IC50 of 0.5 nM/391 nM.
Purity & Quality Control
Choose Selective Endothelin Receptor Inhibitors
Biological Activity
| Description | Macitentan is an orally active, non-peptide, dual ETA/ETB (endothelin) receptor antagonist with IC50 of 0.5 nM/391 nM. | ||||
|---|---|---|---|---|---|
| Targets |
|
||||
| In vitro |
Macitentan achieves full inhibition of intracellular calcium increase induced by ET-1 on primary human pulmonary smooth muscle cells with approximate IC50 of 1 nM. Macitentan inhibits ET-1-induced contractions on isolated rat aortic rings or S6c-induced contractions on isolated rat tracheal rings with pA2 of 7.6 and 5.9, respectively. [1] |
||||
| In vivo | Macitentan administered to normotensive rats, increases plasma ET-1 concentration, which occurred at a 10-fold lower dose than with bosentan. Macitentan dose-dependently decreases mean arterial blood pressure in hypertensive DOCA-salt rats with a maximal effect of -26 mm Hg at a dose of 10 mg/kg and a ED50 of 1mg/kg. At the maximal effective dose, the duration of the blood pressure response to Macitentan is approximately 40 hr. Macitentan orally administrated dose-dependently preventes the development of pulmonary hypertension and the development of right ventricle hypertrophy with a maximal efficacy of 30 mg/kg/day in monocrotaline rat model of pulmonary hypertension. Chronic oral administration of Macitentan at 30 mg/kg/day significantly improves the 42-day survival in monocrotaline rats (83 vs 50% survival in macitentan vs vehicle; 66% reduction of mortality at 42 days). [1] Macitentan (30 mg/kg/day) treated for 24 h partially prevents the development of renal vasoconstriction and increases renal blood flow in streptozotocin-induced diabetic rat model. Macitentan increases glomerular filtration rate and decreases filtration fraction, and attenuates vascular and tubulo-interstitial lesions and also glomerular damage. [1] Macitentan (25 mg/kg/day, p.o.) attenuates the increase of renal, cardiac and retinal ET-1, TGF-β1, VEGF, FN, EDB+FN, collagenα-I(IV) mRNA expression along with increased FN, collagen protein and NF-κB activation induced by type 2 diabetes in db/db mice. Macitentan also ameliorates mesangial expansion, cardiac dysfunction and the increased expression of ANP and BNP in these diabetic mice. [2] Macitentan (100mg/kg) treatment combined with paclitaxel (5 mg/kg) reduced tumor incidence (5/9 vs 9/9 of paclitaxel along) and further reduces tumor weight (median [range]: 0.1 vs 0.4 g of paclitaxel along) and incidences of ascites (0/9 vs 4/9 of paclitaxel along) in SKOV3ip1 ovarian cancer model when compared with paclitaxel alone. Macitentan plus paclitaxel inhibits the phosphorylation of ETRs and suppresses the survival pathways of tumor cells by decreasing the levels of pVEGFR2, pAkt, and pMAPK. Macitentan enhances effects of paclitaxel on tumor cells dividing (Brud+ cells: 18.5 vs 30.8 of paclitaxel along) and apoptosis (TUNEL+ cells: 195 vs 150 of paclitaxel along). [3] |
Protocol
Solubility (25°C)
| In vitro | DMSO | 100 mg/mL (169.98 mM) |
|---|---|---|
| Water | Insoluble | |
| Ethanol | Insoluble |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 588.27 |
|---|---|
| Formula | C19H20Br2N6O4S |
| CAS No. | 441798-33-0 |
| Storage | powder |
| in solvent | |
| Synonyms | ACT 064992 |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03775421 | Not yet recruiting | Congenital Heart Disease With Fontan Circulation | Actelion|Covance|Henry Ford Health System|Almac Clinical Technologies|ActiGraph LLC|Medidata Solutions | April 23 2019 | Phase 3 |
| NCT03775421 | Not yet recruiting | Congenital Heart Disease With Fontan Circulation | Actelion|Covance|Henry Ford Health System|Almac Clinical Technologies|ActiGraph LLC|Medidata Solutions | April 23 2019 | Phase 3 |
| NCT03809650 | Recruiting | Chronic Thromboembolic Pulmonary Hypertension (CTEPH) | Actelion|EPS Corporation|Imepro Inc.|General Laboratory BML Inc.|Mitsubishi Logistics Corporation | January 8 2019 | Phase 3 |
| NCT03809650 | Recruiting | Chronic Thromboembolic Pulmonary Hypertension (CTEPH) | Actelion|EPS Corporation|Imepro Inc.|General Laboratory BML Inc.|Mitsubishi Logistics Corporation | January 8 2019 | Phase 3 |
| NCT03714815 | Enrolling by invitation | Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease | Actelion|Almac Clinical Technologies LLC|Frontier Science & Technology Research Foundation Inc.|Covance Central Laboratory Services LP|Chiltern International Ltd.|WorldCare Clinical LLC|AcitGraph|Medidata Solutions | December 7 2018 | Phase 2 |
| NCT03714815 | Enrolling by invitation | Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease | Actelion|Almac Clinical Technologies LLC|Frontier Science & Technology Research Foundation Inc.|Covance Central Laboratory Services LP|Chiltern International Ltd.|WorldCare Clinical LLC|AcitGraph|Medidata Solutions | December 7 2018 | Phase 2 |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
